Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
psoriatic arthritis
Pharma
With win over AbbVie's Skyrizi, UCB's Bimzelx remains undefeated
UCB's IL-17 inhibitor Bimzelx has topped Skyrizi, as a phase 3b study of patients with active psoriatic arthritis has achieved its primary endpoint.
Kevin Dunleavy
Mar 11, 2026 11:29am
FDA expands label for BMS' Sotyktu to treat psoriatic arthritis
Mar 9, 2026 11:16am
UCB reaps the rewards of fast-growing Bimzelx
Feb 27, 2026 11:51am
Lilly touts Zepbound-Taltz combo after psoriasis trial victory
Feb 18, 2026 8:30am
Lilly touts Zepbound-Taltz combo in patients with obesity, PsA
Jan 8, 2026 2:00pm
Trial results enhance BMS bid for Sotyktu in psoriatic arthritis
Mar 10, 2025 8:38am
